Dark

Check out our API

CRL
Charles River Laboratories International, Inc.
stock NYSE

At Close

Jul 27, 2026 3:59:59 PM EDT

224.21USD-1.046%(-2.37)720,332

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 24, 2026 8:06:30 AM EDT

232.79USD+2.741%(+6.21)0

After-hours

Jul 27, 2026 4:10:30 PM EDT

224.30USD+0.040%(+0.09)87,965

OverviewOptionsHistoricalExchangesShortsTrends

CRL Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

CRL Specific Mentions

As of Jul 28, 2026 5:29:03 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

4 days ago • u/Free_Piglet_4632 • r/pennystocks • otlk_fda_decision • :snoo_dealwithit: General Discussion :snoo_dealwithit: • B

Hey Guys, I have about 15k shares of OTLK at 1.37$.
I’ve been holding since last year and held during the CRL. This time I want to be more cautious as I want to use the money somewhere else. So as the decisions comes after hours all the time, is there a way as a retail investor on Robinhood I can have after hours stop loss to ensure I’m not holding a back in case of another CRL or denial. What do I do ?

5 days ago • u/ivulcan1 • r/biotech_stocks • otlk_fda_decision_on_july_29_what_are_your • C

I don’t have IQVIA data but I doubt it is the primary drug given for this indication. Eylea was a 10B dollar brand and now with biosimilars on the market it’s gotten substantially cheaper too which probably only increased its market share.
You’re right its efficacy is well known and it was inferior compared to Lucentis at the 8 week primary endpoint. With that being said I wouldn’t be too surprised if it’s approved, as I said I have no experience with FDRRs. If I had to bet though I still think a 4th CRL is most likely.
Commercially Avastin has and is used because it’s cheap. Good luck getting payers to pay 10x for ONS-5010. Biosimilar Eylea is also going to dominate the market as it continues getting cheaper

4 days ago • u/Free_Piglet_4632 • r/pennystocks • otlk_fda_decision • :snoo_dealwithit: General Discussion :snoo_dealwithit: • B

Hey Guys, I have about 15k shares of OTLK at 1.37$.
I’ve been holding since last year and held during the CRL. This time I want to be more cautious as I want to use the money somewhere else. So as the decisions comes after hours all the time, is there a way as a retail investor on Robinhood I can have after hours stop loss to ensure I’m not holding a back in case of another CRL or denial. What do I do ?

5 days ago • u/ivulcan1 • r/biotech_stocks • otlk_fda_decision_on_july_29_what_are_your • C

I don’t have IQVIA data but I doubt it is the primary drug given for this indication. Eylea was a 10B dollar brand and now with biosimilars on the market it’s gotten substantially cheaper too which probably only increased its market share.
You’re right its efficacy is well known and it was inferior compared to Lucentis at the 8 week primary endpoint. With that being said I wouldn’t be too surprised if it’s approved, as I said I have no experience with FDRRs. If I had to bet though I still think a 4th CRL is most likely.
Commercially Avastin has and is used because it’s cheap. Good luck getting payers to pay 10x for ONS-5010. Biosimilar Eylea is also going to dominate the market as it continues getting cheaper

Share